News and Reports
-
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
28 June 2022Download -
Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368
22 June 2022Download -
Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC
16 June 2022Download -
Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic
14 June 2022Download -
Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension
8 June 2022Download -
Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion in cash
3 June 2022Download -
Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases
2 June 2022Download -
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
26 May 2022Download -
Pfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion deal
10 May 2022Download -
NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China
3 May 2022Download -
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
2 May 2022Download -
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF
26 April 2022Download -
SWIXX and JAZZ expand partnership
19 April 2022Download -
SWIXX and Blueprint Medicines enter into CEE + Greece agreement for AYVAKYT® (avapritinib)
11 April 2022Download -
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
8 April 2022Download -
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
29 March 2022Download -
Aculys Pharma Closes US$24 Million Series B Financing Joined by Domestic and Foreign Investors
28 March 2022Download -
Pharmacy Marketplace 1000Farmacie Closes $15M Series A Financing Round Led by P101 SGR and HBM Healthcare Investments
7 February 2022Download -
NEURELIS Signs Exclusive Licensing Agreement with ACULYS PHARMA for the Development and Commercialization of VALTOCO® (DIAZEPAM NASAL SPRAY) in Japan and the Asia-Pacific Region
25 January 2022Download -
Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer
11 January 2022Download -
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer
11 January 2022Download -
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS
11 January 2022Download -
SWIXX SELECTED AS GILEAD’S BALTIC PARTNER
16 December 2021Download -
SWIXX SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH SANOFI FOR FOURTEEN CEE COUNTRIES
13 December 2021Download -
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial
13 December 2021Download